Nidan Laboratories and Healthcare Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Nidan Laboratories and Healthcare Limited's yearly results (2022–2025), compared with companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹822 of operating cash. Higher than almost all companies in India.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 8.0 times. Higher than 93% of companies in India.
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: ₹2 per ₹100 of sales comes from others' credit, against ₹13 tied up three years earlier. Less money tied up than 89% of companies in India.
Where ₹100 of sales goes
Latest year (Mar 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹822Over the last 3 years, every ₹100 of reported profit came with ₹822 of operating cash.
Higher than almost all companies in India.
Self-Funding Ratio
8.0×Over the last 3 years its own operating cash covered its investment spending (capex) 8.0 times.
Higher than 93% of companies in India.
Cash Locked Ratio
−₹2Money owed to suppliers is larger than money owed by customers plus stock: ₹2 per ₹100 of sales comes from others' credit, against ₹13 tied up three years earlier.
Less money tied up than 89% of companies in India.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Less steady than 78% of companies in India.
Growth Efficiency Ratio
—Sales fell 17%
Sales fell 17% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-17% / -6%In 3 years sales changed by -17% while total assets changed by -6%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.3×Debt due within a year is covered 0.3 times by its yearly operating cash.
Lower than 63% of companies in India.
Cash Cushion Ratio
−52%Debt, after subtracting cash, equals 52% of its market value (net debt).
Lower than 86% of companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 81% of companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 84% of companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Nidan Laboratories and Healthcare Limited owes ₹0.18 for every ₹1 it owns. Nidan Laboratories and Healthcare Limited returned to profit in the year to Mar 2025, after a loss the year before.
Compared with companies in India · latest annual results Mar 2025.
P/E ratio
30.6Investors pay ₹30.6 for every ₹1 of Nidan Laboratories and Healthcare Limited's yearly profit, higher than 63% of companies in India.
P/B ratio
0.26The share price is 0.26 times Nidan Laboratories and Healthcare Limited's book value per share, lower than 98% of companies in India.
Market cap
₹18 CrThe total market value of all of Nidan Laboratories and Healthcare Limited's shares at today's price (share price × number of shares), smaller than 98% of companies in India. PosiCap size class: Nano Cap.
Net worth (book value)
₹68 CrWhat Nidan Laboratories and Healthcare Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2025).
Book value per share
₹49.05Net worth divided by the number of shares. The share price of ₹12.65 is 0.3 times this, which is the P/B above.
Owes vs Owns
0.18×Nidan Laboratories and Healthcare Limited owes ₹0.18 for every ₹1 it owns (low), lower than 87% of companies in India.
Revenue growth
+1%Revenue rose 1% in the year to Mar 2025, and shrank 6% a year on average over 3 years.
Profit growth
Back to profitNidan Laboratories and Healthcare Limited returned to profit in the year to Mar 2025, after a loss the year before.
Profit margin
8.1%Nidan Laboratories and Healthcare Limited keeps ₹8 of every ₹100 of revenue as net profit.
Cash quality
1.2×Cash from Nidan Laboratories and Healthcare Limited's business was 1.2× its reported profit in the year to Mar 2025 — its profit turned into cash.
Interest cover
1.3×Nidan Laboratories and Healthcare Limited's operating profit covered its interest costs 1.3 times in the year to Mar 2025.
Cash vs debt
Net debtNidan Laboratories and Healthcare Limited had ₹9 Cr more debt than cash (net debt) at Mar 2025.
Questions
What is Nidan Laboratories and Healthcare Limited's P/E ratio?
Investors pay ₹30.6 for every ₹1 of Nidan Laboratories and Healthcare Limited's yearly profit, higher than 63% of companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Nidan Laboratories and Healthcare Limited: ₹18 Cr ÷ ₹68 Cr (31 Mar 2025) = 0.3.
How much does Nidan Laboratories and Healthcare Limited owe compared with what it owns?
Nidan Laboratories and Healthcare Limited owes ₹0.18 for every ₹1 it owns (low), lower than 87% of companies in India.
Is Nidan Laboratories and Healthcare Limited's revenue growing?
Revenue rose 1% in the year to Mar 2025, and shrank 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.